{"id":"alpha-ergocryptine","rwe":[],"tags":[{"label":"alpha-Ergocryptine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(3) dopamine receptor","category":"target"},{"label":"DRD3","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"HTR1A","category":"gene"},{"label":"Active","category":"status"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Agonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:43:08.967238","allNames":"ergocryptine","offLabel":[],"synonyms":["alpha ergocryptine","ergocryptine","ergokryptine","alpha-Ergocryptine","alpha-Ergokryptine"],"timeline":[],"brandName":"Ergocryptine","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 6, Cytochrome P450 2C9, 5-hydroxytryptamine receptor 1A","targets":[{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor","isPrimary":true,"activityType":"Ki","activityValue":9.699},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"}],"modality":"Small Molecule","drugClass":"alpha-Ergocryptine","explanation":"Think of dopamine like a messenger that helps control movement, mood, and other functions. When Ergocryptine binds to the D(3) receptor, it can either increase or decrease the amount of dopamine that's released, depending on the situation. This can help treat conditions related to dopamine imbalances, but it's a complex process that requires careful medical supervision.","oneSentence":"Ergocryptine works by binding to the D(3) dopamine receptor, which helps regulate dopamine activity in the brain.","technicalDetail":"Ergocryptine acts as a selective agonist at the D(3) dopamine receptor, which is a subtype of dopamine receptor that plays a critical role in regulating dopamine activity in the brain. By activating this receptor, Ergocryptine can modulate dopamine release and influence various physiological processes."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ergocryptine","title":"Ergocryptine","extract":"Ergocryptine is an ergopeptine and one of the ergoline alkaloids. It is isolated from ergot or fermentation broth and it serves as starting material for the production of bromocriptine. Two isomers of ergocryptine exist, α-ergocryptine and β-ergocryptine. The beta differs from the alpha form only in the position of a single methyl group, which is a consequence of the biosynthesis in which the proteinogenic amino acid leucine is replaced by isoleucine. β-Ergocryptine was first identified in 1967 by Albert Hofmann. Ergot from different sources have different ratios of the two isomers."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/885","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=alpha-Ergocryptine","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Ergocryptine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:38:28.967698","biosimilars":[],"competitors":[{"drugName":"alfentanil","drugSlug":"alfentanil","fdaApproval":"1986-12-29","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"alvimopan","drugSlug":"alvimopan","fdaApproval":"2008-05-20","patentExpiry":"Feb 12, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"anileridine","drugSlug":"anileridine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"buprenorphine","drugSlug":"buprenorphine","fdaApproval":"1981-12-29","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"butorphanol","drugSlug":"butorphanol","fdaApproval":"1978-08-22","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cannabidiol","drugSlug":"cannabidiol","fdaApproval":"2018-06-25","patentExpiry":"Oct 13, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"alpha-ergocryptine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alfentanil","brandName":"alfentanil","genericName":"alfentanil","approvalYear":"1986","relationship":"same-target"},{"drugId":"alvimopan","brandName":"alvimopan","genericName":"alvimopan","approvalYear":"2008","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"anileridine","brandName":"anileridine","genericName":"anileridine","approvalYear":"","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"buprenorphine","brandName":"buprenorphine","genericName":"buprenorphine","approvalYear":"1981","relationship":"same-target"},{"drugId":"butorphanol","brandName":"butorphanol","genericName":"butorphanol","approvalYear":"1978","relationship":"same-target"},{"drugId":"cannabidiol","brandName":"cannabidiol","genericName":"cannabidiol","approvalYear":"2018","relationship":"same-target"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"60972B4V0Y","CHEBI":"CHEBI:10276","UMLSCUI":"C0102544","ChEMBL_ID":"CHEMBL1403281","PUBCHEM_CID":"134551","MESH_SUPPLEMENTAL_RECORD_UI":"C100269"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":293,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Ergocryptine is an ergopeptine and ergoline alkaloid isolated from ergot or fermentation broth, serving as a starting material for the production of bromocriptine. Two isomers of ergocryptine exist, α-ergocryptine and β-ergocryptine, which differ by the position of a single methyl group.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}